Trials / Unknown
UnknownNCT01291823
Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer
A Phase II Study of Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 70 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Elderly patients with esophageal cancer will receive thoracic radiation therapy 54-60Gy over 30 fractions, and concurrent with Gefitinib.
Detailed description
Purpose: to evaluate the efficacy and toxicity of a concomitant treatment using EGFR-TKI and thoracic radiation in elderly patients with esophageal Cancer. Methods:Patients(\>70 years old) with esophageal Cancer will receive thoracic radiation therapy 54-60 Gy over 30 fractions and concurrent with gefitinib 250mg/day.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | gefitinib | gefitinib 250mg/day |
| RADIATION | Thoracic radiotherapy | Thoracic radiotherapy 54-60Gy over 30 fraction |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2012-12-01
- Completion
- 2014-12-01
- First posted
- 2011-02-08
- Last updated
- 2011-02-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01291823. Inclusion in this directory is not an endorsement.